Costantini DL[au] - Search Results

Year	Number of Results
2005	1
2007	2
2008	2
2009	2
2010	2
2013	1
2014	1
2015	1
2016	1
2023	0

1

Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications.

Costantini DL, Hu M, Reilly RM. Costantini DL, et al. Cancer Biother Radiopharm. 2008 Feb;23(1):3-24. doi: 10.1089/cbr.2007.0430. Cancer Biother Radiopharm. 2008. PMID: 18298325 Review.

2

A Pilot Study of 18F-FLT PET/CT in Pediatric Lymphoma.

Costantini DL, Vali R, McQuattie S, Chan J, Punnett A, Weitzman S, Shammas A, Charron M. Costantini DL, et al. Int J Mol Imaging. 2016;2016:6045894. doi: 10.1155/2016/6045894. Epub 2016 May 26. Int J Mol Imaging. 2016. PMID: 27313888 Free PMC article.

3

The role of ultrasound in the follow-up of children with differentiated thyroid cancer.

Vali R, Rachmiel M, Hamilton J, El Zein M, Wasserman J, Costantini DL, Charron M, Daneman A. Vali R, et al. Among authors: costantini dl. Pediatr Radiol. 2015 Jul;45(7):1039-45. doi: 10.1007/s00247-014-3261-0. Epub 2014 Dec 19. Pediatr Radiol. 2015. PMID: 25524437

4

Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.

Costantini DL, Vali R, Chan J, McQuattie S, Charron M. Costantini DL, et al. AJR Am J Roentgenol. 2013 Feb;200(2):408-13. doi: 10.2214/AJR.12.8930. AJR Am J Roentgenol. 2013. PMID: 23345365

5

18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.

McLarty K, Fasih A, Scollard DA, Done SJ, Vines DC, Green DE, Costantini DL, Reilly RM. McLarty K, et al. Among authors: costantini dl. J Nucl Med. 2009 Nov;50(11):1848-56. doi: 10.2967/jnumed.109.067231. Epub 2009 Oct 16. J Nucl Med. 2009. PMID: 19837760 Free article.

6

The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient.

Costantini DL, Arruda EP, Agarwal P, Kim KH, Zhu Y, Zhu W, Lebel M, Cheng CW, Park CY, Pierce SA, Guerchicoff A, Pollevick GD, Chan TY, Kabir MG, Cheng SH, Husain M, Antzelevitch C, Srivastava D, Gross GJ, Hui CC, Backx PH, Bruneau BG. Costantini DL, et al. Cell. 2005 Oct 21;123(2):347-58. doi: 10.1016/j.cell.2005.08.004. Cell. 2005. PMID: 16239150 Free PMC article.

7

Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.

Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM. Costantini DL, et al. J Nucl Med. 2010 Jul;51(7):1084-91. doi: 10.2967/jnumed.109.072389. Epub 2010 Jun 16. J Nucl Med. 2010. PMID: 20554744 Free article.

8

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.

Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. Costantini DL, et al. J Nucl Med. 2007 Aug;48(8):1357-68. doi: 10.2967/jnumed.106.037937. Epub 2007 Jul 13. J Nucl Med. 2007. PMID: 17631548 Free article.

9

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.

Costantini DL, Villani DF, Vallis KA, Reilly RM. Costantini DL, et al. J Nucl Med. 2010 Mar;51(3):477-83. doi: 10.2967/jnumed.109.069716. Epub 2010 Feb 11. J Nucl Med. 2010. PMID: 20150272 Free article.

10

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.

Costantini DL, Bateman K, McLarty K, Vallis KA, Reilly RM. Costantini DL, et al. J Nucl Med. 2008 Sep;49(9):1498-505. doi: 10.2967/jnumed.108.051771. Epub 2008 Aug 14. J Nucl Med. 2008. PMID: 18703606 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results